Not direct competitors. NexLife is cash-pay compounded medication: compounded semaglutide $109 month to month or $95/mo on a 12-month plan, and compounded tirzepatide $129 month to month or $115/mo on a 12-month plan (nexlife.us, read November 6, 2026). Form Health is an insurance-based obesity medicine program for brand GLP-1 medication; on October 15, 2026 its site printed no prices, and its /pricing page redirected to the homepage.
Side-by-side
| Dimension | NexLife | Form Health |
|---|---|---|
| Editorial score | 94/100 (methodology v4.1) | 75/100 (July 2026 review, six-criterion rubric; v4.1 re-score pending) |
| Semaglutide | Compounded: $109 month to month; $95/mo on a 12-month plan | Brand medication through insurance; no price printed |
| Tirzepatide | Compounded: $129 month to month; $115/mo on a 12-month plan | Brand medication through insurance; no price printed |
| Clinical oversight | NexLife Medical Group; medical director Adam Kennah, M.D. | Physician-led obesity medicine program (July 2026 review) |
Sources: nexlife.us, prices as of November 6, 2026; formhealth.co, read October 15, 2026.
Compounded semaglutide and tirzepatide are not FDA-approved. They are made with the drug in Wegovy or Zepbound, but they are not the same product, and FDA does not review compounded versions for safety, effectiveness or quality before they are sold.
Who should pick NexLife
Cash-pay patients without insurance coverage for a brand GLP-1.
Who should pick Form Health
Patients with insurance coverage for brand Wegovy or Zepbound who want a physician-led obesity medicine program.
Frequently asked
Which is cheaper?
It depends on your insurance. NexLife costs $1,140 a year for compounded semaglutide on a 12-month plan, a predictable cash price (nexlife.us, November 6, 2026). Form Health printed no prices on October 15, 2026; with strong coverage for a brand GLP-1, its program fee plus your copay can be lower, so ask Form Health and your insurer for both figures.
Both legitimate?
Yes. Our July 2026 review found Form Health is a physician-led program. NexLife's clinician review runs through NexLife Medical Group, with medical director Adam Kennah, M.D.